Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Simple Search

Search Type: Criteria:

You could also try: limits (518)

BRC Research-imaging-proposal-form_v2 2025 FINAL

Description: BRC Research Imaging Proposal form The BRC Research Imaging Proposal form should be completed by the chief/principal investigator of an
Url: /Media/Southampton-Clinical-Research/Downloads/BRC-Research-imaging-proposal-form-v2-2025-FINAL.docx

BRC Research-imaging-proposal-form_v1 FINAL 10.12.2024

Description: BRC Research Imaging Proposal form The BRC Research Imaging Proposal form should be completed by the chief/principal investigator of an
Url: /Media/Southampton-Clinical-Research/Grants/Download/BRC-Research-imaging-proposal-form-v1-FINAL-10.12.2024.docx

BRC Research-imaging-proposal-form_v1 FINAL 10.12.2024

Description: BRC Research Imaging Proposal form The BRC Research Imaging Proposal form should be completed by the chief/principal investigator of an
Url: /Media/Southampton-Clinical-Research/Downloads/BRC-Research-imaging-proposal-form-v1-FINAL-10.12.2024.docx

DVdSC (weekly cycles 9 onwards) DaratumumabSC-Bortezomib-Dexamethasone Ver1

Description: Chemotherapy Protocol Myeloma DVd SC (weekly) Bortezomib Daratumumab Dexamethasone Cycles 9 onwards Regimen • Myeloma – Bortezomib with daratumumab and dexamethasone Indication • Daratumumab
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVdSC-weekly-cycles-9-onwards-DaratumumabSC-Bortezomib-Dexamethasone-Ver1.pdf

DRD Daratumumab-Lenalidomide-Dexamethasone

Description: Chemotherapy Protocol Myeloma DRD Daratumumab-Lenalidomide-Dexamethasone Regimen • Myeloma – DRD Daratumumab-Lenalidomide-Dexamethasone Indication • Daratumumab in combination with lenalidomide and dexamethasone
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DRD-Daratumumab-Lenalidomide-Dexamethasone.pdf

NIHR RTB_IBHO_PIS-ICF_v1.4_12SEP2024_Localised

Description: PARTICIPANT INFORMATION SHEET Improving Black Health Outcomes (IBHO) NIHR BioResource Version 1.4, 12 Sep 2024 Reading time: 20 minutes This
Url: /Media/Southampton-Clinical-Research/Downloads/NIHR-RTB-IBHO-PIS-ICF-v1.4-12SEP2024-Localised.pdf

DVd-T SC Bortezomib-Daratumumab-Dexamethasone-Thalidomide v1

Description: Details of the Chemotherapy Protocol for Myeloma.
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVd-T-SC-Bortezomib-Daratumumab-Dexamethasone-Thalidomide.pdf

DVdSC (weekly cycles1-8) Bortezomib-Daratumumab-Dexamethasone Ver1

Description: Chemotherapy Protocol Myeloma DVd SC (weekly cycles 1-8) Bortezomib-Daratumumab-Dexamethasone Regimen • Myeloma – DVd SC (weekly cycles 1-8) bortezomib
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVdSC-weekly-cycles1-8-Bortezomib-Daratumumab-Dexamethasone-Ver1.pdf

Daratumumab SC Ver1

Description: Chemotherapy Protocol Myeloma Daratumumab Subcutaneous Regimen • Myeloma – Daratumumab (SC) Indication • Daratumumab monotherapy is recommended as an option for treating relapsed and
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/Daratumumab-SC-Ver1.pdf

ACCORD-2 example sub-protocol

Description: CONFIDENTIAL ACCORD-2-002 - Sub protocol for Bemcentinib (Amendment 01) TITLE PAGE Master Protocol Title: ACCORD-2: A Multicentre, Seamless, Phase
Url: /Media/Southampton-Clinical-Research/COVID-19/ACCORD/ACCORD-2-example-sub-protocol.pdf

11 to 20 of 26

Previous 1 2 3 Next